CRIS Curis Inc

Price (delayed)

$6.32

Market cap

$37.25M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.58

Enterprise value

$9.78M

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of ...

Highlights
CRIS's debt is down by 32% YoY and by 11% from the previous quarter
Curis's EPS has increased by 22% YoY and by 4.2% QoQ
The equity has plunged by 74% YoY and by 52% from the previous quarter
CRIS's quick ratio has dropped by 59% year-on-year and by 13% since the previous quarter

Key stats

What are the main financial stats of CRIS
Market
Shares outstanding
5.89M
Market cap
$37.25M
Enterprise value
$9.78M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.94
Price to sales (P/S)
3.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1
Earnings
Revenue
$9.81M
EBIT
-$47.73M
EBITDA
-$46.1M
Free cash flow
-$39.47M
Per share
EPS
-$8.58
Free cash flow per share
-$6.82
Book value per share
$1.61
Revenue per share
$1.7
TBVPS
$9.17
Balance sheet
Total assets
$62.02M
Total liabilities
$52.56M
Debt
$2.49M
Equity
$9.46M
Working capital
$34.76M
Liquidity
Debt to equity
0.26
Current ratio
4.08
Quick ratio
3.79
Net debt/EBITDA
0.6
Margins
EBITDA margin
-469.8%
Gross margin
97.6%
Net margin
-486.4%
Operating margin
-501.2%
Efficiency
Return on assets
-60.9%
Return on equity
-224.8%
Return on invested capital
-136.1%
Return on capital employed
-94.1%
Return on sales
-486.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRIS stock price

How has the Curis stock price performed over time
Intraday
2.43%
1 week
-8.01%
1 month
-20.6%
1 year
-60.62%
YTD
-50.43%
QTD
-8.41%

Financial performance

How have Curis's revenue and profit performed over time
Revenue
$9.81M
Gross profit
$9.58M
Operating income
-$49.17M
Net income
-$47.73M
Gross margin
97.6%
Net margin
-486.4%
The net income is up by 8% year-on-year
The revenue has declined by 6% year-on-year and by 2.1% since the previous quarter
The gross profit has contracted by 6% YoY and by 2.4% from the previous quarter
CRIS's operating margin is down by 5% year-on-year and by 3.9% since the previous quarter

Growth

What is Curis's growth rate over time

Valuation

What is Curis stock price valuation
P/E
N/A
P/B
3.94
P/S
3.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1
Curis's EPS has increased by 22% YoY and by 4.2% QoQ
The equity has plunged by 74% YoY and by 52% from the previous quarter
The price to book (P/B) is 6% higher than the last 4 quarters average of 3.7
CRIS's price to sales (P/S) is 83% lower than its 5-year quarterly average of 21.8 and 40% lower than its last 4 quarters average of 6.2
The revenue has declined by 6% year-on-year and by 2.1% since the previous quarter

Efficiency

How efficient is Curis business performance
CRIS's return on equity has dropped by 117% year-on-year and by 33% since the previous quarter
The ROIC has plunged by 80% YoY and by 26% from the previous quarter
The company's return on assets fell by 33% YoY and by 11% QoQ
Curis's return on sales has increased by 2.9% YoY but it has decreased by 2.8% QoQ

Dividends

What is CRIS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRIS.

Financial health

How did Curis financials performed over time
The company's total assets is 18% higher than its total liabilities
CRIS's quick ratio has dropped by 59% year-on-year and by 13% since the previous quarter
The current ratio has dropped by 58% year-on-year and by 10% since the previous quarter
CRIS's debt is 74% less than its equity
The debt to equity has soared by 160% YoY and by 86% QoQ
The equity has plunged by 74% YoY and by 52% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.